Non-small cell lung cancer

Common Name(s)

Non-small cell lung cancer

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Non-small cell lung cancer" for support, advocacy or research.

Cancer Hope Network

To provide one-on-one support to people undergoing treatment for cancer and to their families. We provide this support by training individuals who have recovered from cancer and matching them with cancer patients currently undergoing a similar experience. Through this matching process, we strive to instill hope and to make a difference in their fight against cancer.

Last Updated: 29 Jul 2015

View Details
Free to Breathe

Free to Breathe is a partnership of lung cancer survivors, advocates, researchers, healthcare professionals and industry leaders united in the belief that every person with lung cancer deserves a cure. Free to Breathe is dedicated to doubling lung cancer survival by 2022.

Last Updated: 16 Oct 2014

View Details
Logo
Lung Cancer Foundation of America

LCFA’s mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.

Last Updated: 28 Aug 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Non-small cell lung cancer" for support, advocacy or research.

Cancer Hope Network

To provide one-on-one support to people undergoing treatment for cancer and to their families. We provide this support by training individuals who have recovered from cancer and matching them with cancer patients currently undergoing a similar experience. Through this matching process, we strive to instill hope and to make a difference in their fight against cancer.

http://www.CancerHopeNetwork.org

Last Updated: 29 Jul 2015

View Details
Free to Breathe

Free to Breathe is a partnership of lung cancer survivors, advocates, researchers, healthcare professionals and industry leaders united in the belief that every person with lung cancer deserves a cure. Free to Breathe is dedicated to doubling lung cancer survival by 2022.

http://www.freetobreathe.org

Last Updated: 16 Oct 2014

View Details
Logo
Lung Cancer Foundation of America

LCFA’s mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.

http://www.LCFAmerica.org

Last Updated: 28 Aug 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Non-small cell lung cancer" returned 7198 free, full-text research articles on human participants. First 3 results:

Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
 

Author(s): Min Wei, Qingqing Ye, Xuan Wang, Men Wang, Yan Hu, Yonghua Yang, Jiyuan Yang, Jun Cai

Journal: Medicine (Baltimore). 2018 May;97(19):e0632.

 

Lung cancer is the most common cause of cancer death. About 80% of patients are diagnosed at stage III in the non-small cell lung cancer (NSCLC). It is extremely important to understand the progression of this disease which has low survival times despite the advancing treatment modalities. ...

Last Updated: 31 Dec 1969

Go To URL
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
 

Author(s): Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng

Journal: Medicine (Baltimore). 2018 Apr;97(16):e0460.

 

The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis compared their effectiveness and safety.

Last Updated: 31 Dec 1969

Go To URL
N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5.
 

Author(s): Ye Liang, Wenhua Xu, Shihai Liu, Jingwei Chi, Jisheng Zhang, Aihua Sui, Liping Wang, Zhijuan Liang, Dan Li, Yuanbin Chen, Haitao Niu

Journal: Cell. Physiol. Biochem.. 2018 ;45(5):2054-2070.

 

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential anti-cancer agent due to its selective toxicity. However, many human non-small cell lung cancer (NSCLC) cells are partially resistant to TRAIL, thereby limiting its clinical application. Therefore, there ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Non-small cell lung cancer" returned 832 free, full-text review articles on human participants. First 3 results:

S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol.
 

Author(s): Feiyu Liu, Chaoyang Wang, Tao Hu, Wei Wang

Journal: Medicine (Baltimore). 2018 Apr;97(15):e0397.

 

Lung cancer is the leading cause of cancer-related deaths in the world, and non-small cell lung cancer accounts for > 75% of all lung cancer cases. Cisplatin-based concurrent chemoradiotherapy has become the standard treatment for locally advanced non-small cell lung cancer (NSCLC). ...

Last Updated: 31 Dec 1969

Go To URL
Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
 

Author(s): Jia-Hung Chen, Kang-Yun Lee, Chaur-Jong Hu, Chen-Chih Chung

Journal: Medicine (Baltimore). 2017 Dec;96(50):e9262.

 

Immune checkpoint inhibitors have led to the development of new approaches for cancer treatment with positive outcomes. However, checkpoint blockade is associated with a unique spectrum of immune-related adverse events (irAEs), which may cause irreversible neurological deficits and even death.

Last Updated: 31 Dec 1969

Go To URL
Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.
 

Author(s): Mahmoud Hashim, Boris M Pfeiffer, Robert Bartsch, Maarten Postma, Bart Heeg

Journal: Value Health. 2018 01;21(1):9-17.

 

In previous studies, correlation between overall survival (OS) and surrogate endpoints like objective response rate (ORR) or progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) was poor. This can be biased by crossover and postprogression treatments.

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer
 

Status: Recruiting

Condition Summary: Non-small Cell Lung Cancer

 

Last Updated: 21 Sep 2017

Go to URL
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
 

Status: Recruiting

Condition Summary: Non Small Cell Lung Cancer

 

Last Updated: 28 Aug 2017

Go to URL
Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer
 

Status: Recruiting

Condition Summary: Non Small Cell Lung Cancer

 

Last Updated: 6 Dec 2017

Go to URL